ForCare Clinical Research

The trials here

What the 41 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)9 trials
• Alopecia areata6 trials
• Obesity5 trials
• Hidradenitis suppurativa4 trials
• Migraine4 trials
• Vitiligo3 trials
• Depression2 trials
• Gout2 trials
• Type 2 diabetes2 trials
• Alzheimer disease1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Lyme disease1 trial
• and 3 more

Phase

• Phase 320 trials
• Phase 216 trials
• Phase 2/33 trials
• Phase 42 trials

Status

• Completed24 trials
• Active, not recruiting8 trials
• Terminated3 trials
• Recruiting2 trials
• Withdrawn2 trials
• Enrolling by invitation1 trial
• Not yet recruiting1 trial

Lead sponsor

• Pfizer13 trials
• Eli Lilly and Company10 trials
• Incyte Corporation5 trials
• Amgen2 trials
• Biohaven Therapeutics Ltd.1 trial
• and 10 more

Running trials

• Not yet recruiting

  A Study of Brenipatide in Participants With Major Depressive Disorder

  NCT07928245· Phase 2· Eli Lilly and Company· Source

  Contact: Marlene Hart (principal investigator)

• Recruiting

  Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

  NCT07565428· Phase 3· Minerva Neurosciences· Source

  Contact: Chief Operating Officer

• Recruiting

  A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

  NCT07384975· Phase 2· Navigator Medicines, Inc.· Source

  Contact: Associate Director, Clinical Operations

• Recruiting

  A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

  NCT06873945· Phase 3· Pfizer· Source

• Active, not recruiting

  A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

  NCT06163326· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

  NCT06113445· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

  NCT05995964· Phase 2· Pfizer· Source

• Enrolling by invitation

  A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05735483· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05559359· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

  NCT04743141· Phase 3· Pfizer· Source

• Recruiting

  Randomized Study in Children and Adolescents With Migraine: Acute Treatment

  NCT04649242· Phase 3· Pfizer· Source

• Active, not recruiting

  Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

  NCT03898479· Phase 2/3· Sun Pharmaceutical Industries, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)1 recruiting
• Depression1 recruiting
• Hidradenitis suppurativa1 recruiting
• Schizophrenia1 recruiting

Closed trials

• Withdrawn

  A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

  NCT07357766· Phase 3· Novo Nordisk A/S· Source

• Completed

  Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

  NCT06836063· Phase 2· Suven Life Sciences Limited· Source

• Completed

  A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

  NCT06881836· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Completed

  A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

  NCT06973720· Phase 2· Pfizer· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

  NCT06897202· Phase 2· Pfizer· Source

• Terminated

  Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

  NCT06555328· Phase 2· InflaRx GmbH· Source

• Completed

  A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06602219· Phase 2· DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company· Source

• Completed

  Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

  NCT06603623· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06046729· Phase 2· Eli Lilly and Company· Source

• Completed

  Topical Ruxolitinib Evaluation in Chronic Hand Eczema

  NCT05906628· Phase 2· Incyte Corporation· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

  NCT05822830· Phase 3· Eli Lilly and Company· Source

• Completed

  Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

  NCT05586971· Phase 3· LG Chem· Source

• Withdrawn

  Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

  NCT05233410· Phase 3· Incyte Corporation· Source

• Completed

  Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

  NCT05634811· Phase 3· Pfizer· Source

• Completed

  Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

  NCT05635838· Phase 2· Incyte Corporation· Source

• Completed

  A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

  NCT05583526· Phase 3· Pfizer· Source

• Terminated

  An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

  NCT05399368· Phase 2· RAPT Therapeutics, Inc., a member of the GSK plc group of companies· Source

• Completed

  Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

  NCT05368103· Phase 2· Amgen· Source

• Completed

  A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

  NCT04921969· Phase 3· Incyte Corporation· Source

• Terminated

  A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

  NCT04804033· Phase 2/3· Pfizer· Source

• Completed

  Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

  NCT04511702· Phase 4· Amgen· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Pfizer· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

  NCT04184622· Phase 3· Eli Lilly and Company· Source

• Completed

  Long-Term PF-06651600 for the Treatment of Alopecia Areata

  NCT04006457· Phase 3· Pfizer· Source

• Completed

  A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

  NCT03899259· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Phase 4· Eli Lilly and Company· Source

• Completed

  A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

  NCT03570749· Phase 2/3· Eli Lilly and Company· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source